To study the effects of acute alterations in heart rate and systemic arterial pressure on the mean velocity of left ventricular circumferential fiber shortening (Vcf) and on mean posterior wall velocity (Vpw), we performed ultrasound studies in 25 normal human subjects between the ages of 21 and 29 years. When heart rate was augmented by the administration of intravenous atropine from 64 + 2.2 (SEM) to 98 ± 2.7 beats/min, mean normalized Vcf increased from 1.22 i 0.05 to 1.38 ± 0.06 circumferences (circ)/sec (P < 0.001). Mean normalized Vpw increased from 0.76 + 0.03 to 0.89 ± 0.04 sec1 (P < 0.001). Mean Vcf and mean Vpw uncorrected for end-diastolic diameter increased in a similar fashion (P < 0.01). After atropine administration, systemic arterial pressure was augmented by means of a phenylephrine infusion in 23 subjects by an average of 39 mm Hg (range 20-50 mm Hg). During the phenylephrine infusion, average heart rate decreased from 96 ± 2.6 to 91 ± 3.1 beats/min (NS), while mean normalized Vcf declined from 1.38 ± 0.06 to 1.09 ± 0.05 circ/sec (P < 0.001) and normalized Vpw from 0.89 ± 0.04 to 0.65 ± 0.04 sec`1 (P < 0.001). Nonnormalized velocities exhibited similar alterations (P < 0.01). We conclude that in the normal human subject mean Vcf and mean Vpw are sensitive to acute alterations in heart rate and systemic arterial pressure. Thus, when ultrasound measures are used for serial assessment of left ventricular performance, the level of heart rate and systemic arterial pressure at which studies are obtained must be considered. Further, the sequential use of atropine and phenylephrine, as described in this study, provides an experimental model for the evaluation of the effects of drug treatment and other interventions on left ventricular performance in man.
ECHOCARDIOGRAPHY provides a useful noninvasive method for the assessment of left ventricular performance in man. Although a number of ejection phase indices, including the ejection fraction (EF),1 2 mean normalized posterior wall velocity (Vpw),3 and the normalized mean rate of circumferential fiber shortening (Vcf),' 6 can be derived from the echocardiogram, there is little information concerning the acute effects of alterations in heart rate and systemic arterial pressure on these measures. Therefore, to evaluate the influence of acute changes in heart rate and blood pressure on these echocardiographic ejection phase indices of left ventricular performance, we studied normal subjects in the basal state and after the administration of atropine and phenylephrine.
Methods
Study Design
The study population consisted of 25 normal human volunteers (ten women and 15 men). They were between the ages of 21 and 29 and had no cardiovascular disease as assessed by history and physical examination. The resting electrocardiogram was within normal limits in all subjects. After the subjects were familiarized with the procedures, and informed consent was obtained, an intravenous infusion of 5% dextrose and water was begun using a scalp vein needle inserted into a forearm vein. A baseline echocardiogram and measurements of heart rate and systemic arterial pressure (cuff sphygmomanometer) were obtained. Subsequently, atropine was administered intravenously in a quantity sufficient to raise the heart rate at least 30 beats/min or until a maximum of 1.5 mg had been given. When the heart rate and systemic arterial pressure were stable for at least ten minutes, a second echocardiogram was obtained. At this point, with the heart rate response to increased arterial pressure blocked by atropine, phenylephrine (10 mg diluted in 250 ml of 0.9% NaCl) was infused in 23 subjects over 5 to 10 minutes in a quantity sufficient to raise the systolic arterial pressure approximately 40 mm Hg. With systolic pressure held at this level, a third echocardiogram was ob-tained and the infusion terminated. The total volume of fluid uised in the entire study did not exceed 50 ml.
Recording Technique
Echocardiograms were recorded with a Picker ultrasonoscope uitilizing a 2. 25 MHz, 1.27 cm transducer focused at 7.5 cm, with a repetition rate of 1000 impulses/sec. The output signal was recorded on a Honeywell Visicorder Oscillograph model 1856. Each patient had an electrocardiogram recorded simultaneously with the echogram. Echocardiograms were obtained with the subjects in the supine or partial left lateral decubitus position. The transducer was placed at the third or fourth intercostal space, just to the left of the sternum. With the transducer directed posteriorly and slightly medially, the mitral valve echo was identified; the transducer was then rotated inferolaterally to obtain echoes from the endocardial surfaces of the left side of the interventricular septum and the posterior wall. Left ventricular dimensions were measured at the level of the posterior mitral valve supporting apparatus, which was identified by its continuity with the posterior mitral valve leaflet on scanning superiorly and medially. Fragments of the mitral valve leaflet echoes were also frequently observed ( fig. 1) . In nine subjects a carotid arterial pulse tracing was obtained simultaneously with the echocardiogram. The carotid arterial pulse tracing was obtained with a bell held manually over the carotid artery and connected by an air-filled tube to a Statham P23Db strain gauge manometer.
A Measurements and Calculations
Left ventricular dimensions were measured between the endocardial surfaces of the posterior wall and the left side of the septum (fig. IA) . The end-diastolic dimension (EDD) was measured at a point on the time motion scan coincident with the peak of the R wave of the simultaneously recorded ECG. The end-systolic dimension (ESD) was defined as the smallest distance separating the left ventricular endocardial surfaces even if the points of maximum excursion were not exactly opposed.5' 6 Initially, the left ventricular ejection time (ET) was measured as the length of time from the peak of R wave to the maximum anterior excursion of the left ventricular posterior wall, less 50 msec for the preejection period.5 Subsequently, it became technically feasible to record a carotid arterial pulse tracing simultaneous with the echocardiogram. The validity of the earlier method of measuring ET was confirmed for the basal state and under conditions of altered heart rate and afterload in the nine subjects in whom ET was obtained from the simultaneously recorded carotid arterial pulse tracing, and the method of determining the ejection time in no way altered the results obtained. In addition, the sex of the subject did not influence the results of the study.
The 
Results
Increasing Heart Rate After the administration of atropine, heart rate increased in the 25 subjects from an average of 64 ± 2.2 (SEM) to 98 ± 2.7 beats/min (P < 0.001). Systemic systolic arterial pressure also increased from 114 ± 2.0 to 122 + 2.2 mm Hg (P < 0.001). Mean normalized Vcf increased from 1.22 ± 0.05 to 1.38 ± 0.06 circ/sec (P < 0.001, fig. 2 ). Mean Vcf uncorrected for end-diastolic diameter increased in a similar fashion from 5.9 ± 0.2 to 6.4 ± 0.3 cm/sec (P < 0.01). The increase in mean Vcf was paralleled by an increase in mean normalized Vpw from 0.76 + 0.03 to 0.89 ± 0.04 sec`(P < 0.001, fig. 3 ). Nonnormalized mean Vpw increased similarly from 3.7 + 0.1 to 4.1 ± 0.2 cm/sec (P < 0.01). EDD also decreased significantly from 49.1 ± 1.0 to 47.1 ± 1.2 mm (P < 0.01), consistent with decreased filling time associated with a higher heart rate. EF did not change significantly. Individual patient data are detailed in table 1 and a typical response to increased heart rate is depicted in figure 1B . Following the infusion of phenylephrine, systolic arterial pressure increased in 23 subjects by an average of 39 mm Hg (range 20 to 50 mm Hg). The slight decrease in mean heart rate from 98 ± 2.7 to 91 ± 3.1 beats/min was not significant. Mean normalized Vcf declined from 1.38 ± 0.06 to 1.09 ± 0.05 circ/sec (P < 0.001, fig. 2 ). Nonnormalized mean Vcf also decreased from 6.4 ± 0.3 to 5.4 ± 0.2 cm/sec (P < 0.001). Similarly, mean normalized Vpw declined from 0.89 + 0.04 to 0.65 ± 0.04 sec( P < 0.001, fig. 3 ), as did nonnormalized mean Vpw (4.1 + 0.2 vs 3.2 ± 0.2 cm/sec, P < 0.001). EDD also increased significantly from 47.1 ± 1.3 to 49.6 ± 1.1 mm (P < 0.001) and EF showed a significant decline from 76 ± 1.0 to 71 ± 2.0% (P < 0.01). For individual patient data, see table 1 . A typical response to increased systemic arterial pressure is shown in figure 1C .
Discussion Effects of Alterations in Heart Rate
A considerable body of evidence published since the well-known studies of Bowditch7 and Woodworth8 suggests that an augmentation of heart rate, exclusive of alterations produced by exercise, exerts a positive inotropic effect on the myocardium. Studies carried out on excised strips of myocardium,9"-isolated hearts,12 anesthetized preparations,13-17 and human subjects18' 19 25 The influence of chronic increases in heart rate are not known, but data obtained in normal infants indicate that average mean Vcf is higher than in adults with slower basal heart rates. 26 It should be emphasized that the augmentation of heart rate in our study was The usefulness of determinations of mean Vcf for separating normal from abnormal subjects has been well-demonstrated,37 43 44 and the application of the concept of normalized internal shortening velocity to echocardiographic measurements has proved to be a fruitful approach.3 6, 37 The present study confirms observations reported in the normal conscious dog23 and in a small number of patients37 and extends them to normal human subjects in sinus rhythm. These data indicate that internal shortening velocities are useful in the characterization of left ventricular performance in man provided that acute alterations in heart rate and systemic arterial pressure do not occur. Thus, when serial ultrasound studies of left ventricular performance are employed to assess the effects of interventions such as surgical procedures, consideration must be given to the levels of heart rate and systemic arterial pressure at which the recordings are obtained. Finally, the sequential use of atropine and phenylephrine, as described in this study, provides an experimental model in the human subject for assessing the effects of drug therapy and other interventions on left ventricular function in man.
